CMS FHIR Prototype Measure Calculation Tool IG
0.1.0 - CI Build
CMS FHIR Prototype Measure Calculation Tool IG, published by HL7 International - [Some] Work Group. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/mct-ig/ and changes regularly. See the Directory of published versions
Official URL: http://cms.gov/fhir/mct/Measure/DischargedonAntithromboticTherapyQICore4 | Version: 0.1.0 | |||
Draft as of 2022-07-05 | Computable Name: DischargedonAntithromboticTherapyQICore4 | |||
Other Identifiers: http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/guid#755216b2-5fa4-474d-bb29-ae8eaa209460 (use: official), http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms#1095FHIR (use: official) | ||||
Copyright/Legal: Measure specifications are in the Public Domain LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2020 International Health Terminology Standards Development Organisation. All Rights Reserved. |
Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge
The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist. For patients with a stroke due to a cardioembolic source (e.g. atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke. Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.
Id: | DischargedonAntithromboticTherapyQICore4 | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Url: | Discharged on Antithrombotic Therapy QICore | ||||||||||||||||||||||||||
Version: | 0.1.0 | ||||||||||||||||||||||||||
Identifier: |
value: 755216b2-5fa4-474d-bb29-ae8eaa209460 |
||||||||||||||||||||||||||
Identifier: |
value: 1095FHIR |
||||||||||||||||||||||||||
Name: | DischargedonAntithromboticTherapyQICore4 | ||||||||||||||||||||||||||
Title: | Discharged on Antithrombotic Therapy QICore | ||||||||||||||||||||||||||
Status: | draft | ||||||||||||||||||||||||||
Experimental: | false | ||||||||||||||||||||||||||
Scoring: |
system: MeasureScoring code: proportion display: Proportion |
||||||||||||||||||||||||||
Improvement Notation: |
system: MeasureImprovementNotation code: increase |
||||||||||||||||||||||||||
Type: |
system: MeasureType code: process |
||||||||||||||||||||||||||
Date: | 2022-07-05 20:34:35-0600 | ||||||||||||||||||||||||||
Publisher: | HL7 International - [Some] Work Group | ||||||||||||||||||||||||||
Description: | Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge |
||||||||||||||||||||||||||
Populations: |
|
||||||||||||||||||||||||||
Supplemental Data: |
|
||||||||||||||||||||||||||
Jurisdiction: | US | ||||||||||||||||||||||||||
Purpose: | The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist. For patients with a stroke due to a cardioembolic source (e.g. atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke. Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA. |
||||||||||||||||||||||||||
Copyright: | Measure specifications are in the Public Domain LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2020 International Health Terminology Standards Development Organisation. All Rights Reserved. |
||||||||||||||||||||||||||
Disclaimer: | These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The measures and specifications are provided without warranty. |
||||||||||||||||||||||||||
Effective Period: | 2022-01-01..2022-12-31 | ||||||||||||||||||||||||||
Logic Definitions: |
|